Dividend and Profit Distribution - The company plans to distribute a cash dividend of 5.60 CNY per 10 shares, totaling approximately 75.23 million CNY, which represents 30.48% of the net profit attributable to shareholders for the year[4]. - As of December 31, 2024, the company's accumulated undistributed profits amounted to approximately 521.18 million CNY[4]. - The total number of shares eligible for profit distribution is 134,345,456 shares after accounting for repurchased shares[4]. - The company will not issue bonus shares or conduct capital reserve transfers for the 2024 fiscal year[5]. Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year 2023, representing a growth of 20% compared to the previous year[13]. - The company's operating revenue for 2024 reached ¥621,389,216.13, representing a 29.99% increase compared to ¥478,018,082.96 in 2023[23]. - Net profit attributable to shareholders for 2024 was ¥246,859,675.26, up 41.92% from ¥173,948,077.93 in 2023[23]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥217,752,441.57, reflecting a 48.08% increase from ¥147,047,727.73 in 2023[23]. - The gross margin for the year was reported at 60%, an increase from 55% in the previous year, indicating improved operational efficiency[13]. - Basic earnings per share increased to CNY 1.81, up 41.41% from CNY 1.28 in 2023[25]. - The weighted average return on equity rose to 12.74%, an increase of 2.87 percentage points compared to 9.87% in 2023[25]. Research and Development - Research and development expenses accounted for 15.64% of operating revenue, up 4.53 percentage points from 11.11% in 2023[25]. - The company achieved a total R&D investment of ¥97,168,026.39, representing an increase of 82.95% compared to the previous year[81]. - The company has established six major technology platforms, including immunochromatography and PCR detection platforms, to enhance its R&D capabilities[43]. - The company has developed a recombinant antibody platform to ensure quality control for its antibody testing kits[77]. - The company has made significant advancements in protein purification technology, enhancing the stability of production processes[77]. Market Expansion and Strategy - The company is focusing on expanding its market presence in Southeast Asia, targeting a 30% market share within the next two years[13]. - The company plans to invest 100 million RMB in new technology development over the next year to improve diagnostic accuracy[13]. - The company aims to expand its market presence through innovative product development and strategic partnerships in the healthcare sector[50]. - The company plans to increase investment in the international market, striving to become a leading player in the global antigen detection product sector[147]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of $50 million earmarked for potential deals[160]. Compliance and Governance - The company has received a standard unqualified audit report from DaXin Accounting Firm[4]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[3]. - The company is committed to ensuring timely, accurate, and complete information disclosure to maintain a positive image in the capital market[48]. - The company has not reported any major adverse effects from competition with its controlling shareholders[152]. - The company is in compliance with the corporate governance standards set by relevant regulations[152]. Risks and Challenges - The company has outlined potential risks in its management discussion and analysis section[3]. - The company faces risks related to technological upgrades, as new advancements could render existing products obsolete if not addressed timely[91]. - The company is at risk of new product development failures due to the complex and lengthy R&D process in the in vitro diagnostics industry[92]. - The rapid expansion of the company's operations may lead to management challenges if the management structure does not adapt accordingly[95]. Product Development and Innovation - New product development includes the launch of three new respiratory detection kits, which are expected to contribute an additional 200 million RMB in revenue[13]. - The company has successfully registered multiple new products, including the Helicobacter pylori antigen test kit and various biomarkers, expanding its product offerings in both domestic and international markets[44]. - The company has developed a series of respiratory testing products, including the "Full Blood Respiratory Five Item Testing Kit," which detects five pathogens associated with respiratory infections, aiding in early identification and treatment[50]. - The company has developed a combined detection kit for influenza A, influenza B, and COVID-19, which utilizes nasopharyngeal swab samples for early diagnosis and rapid screening[53]. Operational Efficiency - The company has set a target to reduce production costs by 10% through process optimization and supply chain improvements[13]. - The company employs a tiered procurement management system, categorizing raw materials into A, B, and C classes based on their impact on product performance and safety[55]. - The procurement process follows a "just-in-time" model, with departments submitting monthly requests based on safety stock and actual production needs[56]. - The company has implemented strict quality control processes and obtained certifications such as ISO 13485 and CE, ensuring high-quality products[90]. Shareholder Engagement - The company plans to hold its annual shareholder meeting on May 10, 2024, to discuss the 2023 annual report and other key proposals[154]. - The total pre-tax remuneration for executives during the reporting period amounted to 879.32 million yuan[158]. - The company has implemented a stock incentive plan, with core technical personnel receiving stock incentives during the reporting period[159].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 206,965,618.84, a decrease of 26.51% compared to CNY 281,611,655.58 in the same period last year[4] - Net profit attributable to shareholders was CNY 95,289,652.25, down 34.77% from CNY 146,085,284.93 year-on-year[4] - Basic earnings per share decreased to CNY 0.70, down 34.58% from CNY 1.07 in the same period last year[4] - Operating profit for Q1 2025 was CNY 111,740,268.98, down 35.5% from CNY 173,246,246.12 in Q1 2024[20] - Total comprehensive income for Q1 2025 was CNY 95,253,737.06, a decrease of 34.8% compared to CNY 146,148,514.28 in Q1 2024[21] Research and Development - R&D investment totaled CNY 34,547,124.87, representing a significant increase of 57.16% compared to CNY 21,982,120.56 in the previous year[4] - The proportion of R&D investment to operating revenue rose to 16.69%, an increase of 8.88 percentage points from 7.81%[4] - Research and development expenses increased to CNY 34,547,124.87 in Q1 2025, up 57.2% from CNY 21,982,120.56 in Q1 2024[19] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,273,052,624.62, reflecting a 2.74% increase from CNY 2,212,458,840.74 at the end of the previous year[5] - Total current assets as of March 31, 2025, amounted to RMB 2,066,945,047.61, an increase from RMB 1,997,548,379.07 as of December 31, 2024, reflecting a growth of approximately 3.5%[15] - The company's total assets reached RMB 2,273,052,624.62, up from RMB 2,212,458,840.74, indicating an increase of approximately 2.75%[16] - Total liabilities decreased to CNY 210,539,628.59 in Q1 2025 from CNY 219,070,375.95 in Q1 2024, a reduction of 3.4%[19] - The total liabilities increased, with accounts payable rising from RMB 90,927,479.39 to RMB 103,626,956.14, an increase of approximately 14%[16] Cash Flow - The net cash flow from operating activities was CNY 114,756,382.68, a decrease of 7.46% compared to CNY 124,003,396.25 in the previous year[4] - The company reported a cash flow from operating activities of CNY 254,550,052.12 in Q1 2025, reflecting a decline in cash inflow from operations[23] - The total cash inflow from operating activities was $258,908,022.29, compared to $271,290,079.16 in the previous period[24] - The cash and cash equivalents at the end of the period amounted to $368,810,713.21, an increase from $234,026,855.04[25] Shareholder Equity - Shareholders' equity attributable to the parent company increased by 3.47% to CNY 2,062,512,996.03 from CNY 1,993,388,464.79[5] - Total equity attributable to shareholders increased to CNY 2,062,512,996.03 in Q1 2025, up 3.5% from CNY 1,993,388,464.79 in Q1 2024[18] Other Financial Metrics - The weighted average return on net assets decreased by 2.92 percentage points to 4.70% from 7.62%[4] - The company reported non-recurring gains and losses totaling CNY 6,946,527.24 for the period[7] - The company has not reported any significant changes in the top ten shareholders or their shareholding due to securities lending activities[14] - The company’s non-current assets totaled RMB 206,107,577.01, down from RMB 214,910,461.67, reflecting a decrease of approximately 4.0%[16] - The company’s cash flow management appears to be improving, as indicated by the increase in cash and cash equivalents alongside a reduction in accounts receivable[15]

证券代码：688253 证券简称：英诺特 公告编号：2025-015 北京英诺特生物技术股份有限公司 关于增加募投项目实施内容的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京英诺特生物技术股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第二届董事会第九次会议、第二届监事会第九次会议，审议通过了《关于 增加募投项目实施内容的议案》，同意公司增加"体外诊断产品研发项目"实施 内容"新布局技术平台相关的自研、技术引进及产品研发"相关投入。 监事会发表了明确同意的意见，保荐机构华泰联合证券有限责任公司（以下 简称"华泰联合"）出具了明确的核查意见。现将有关事项公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2022 年 4 月 28 日作出的《关于同意北京英诺特生物技术股份有限公司首次公开发行股票注 册的批复》（证监许可[2022]902 号），并经上海证券交易所同意，公司于 2022 年 7 月首次向社会公开发行人民币普通股（A 股）股票 ...

北京英诺特生物技术股份有限公司 2024 年度审计委员会履职情况报告 根据《上市公司治理准则》《上海证券交易所科创板股票上市规则》《上海证 券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关法律法规以 及公司《董事会审计委员会议事规则》的有关规定，公司董事会审计委员会在 2024 年度任期内勤勉尽责，积极开展工作，认真履行职责。现就 2024 年度履职 情况报告如下： 一、审计委员会基本情况 公司第二届董事会审计委员会由独立董事孙健、独立董事董关木、独立董事 胡天龙组成，其中独立董事占比超过二分之一，并由具有专业资格的独立董事孙 健为审计委员会主任委员，全体成员具备能够胜任审计委员会工作职责的专业知 识和行业经验，符合相关法律法规及《上海证券交易所科创板上市公司自律监管 指引第 1 号——规范运作》的规定。 2024 年 6 月，董关木先生因个人原因提出辞职，经第二届董事会第五次会 议及 2024 年第一次临时股东大会审议，补选谢幼华先生为公司第二届董事会独 立董事。谢幼华先生自 2024 年 8 月 20 日起担任公司第二届董事会独立董事、审 计委员会委员、战略委员会委员、薪酬与考核委员会委员 ...

证券代码：688253 证券简称：英诺特 公告编号：2025-014 北京英诺特生物技术股份有限公司关于确认 2024 年 度及预计 2025 年度日常关联交易额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 2025 年 4 月 24 日，公司召开第二届董事会第九次会议及第二届监事会第九 次会议，审议通过了《关于确认 2024 年度及预计 2025 年度日常关联交易额度的 议案》，关联董事叶逢光、张秀杰、LIN YI 回避表决，出席会议的非关联董事人 数为 6 人，不属于"出席董事会会议的非关联董事人数不足 3 人的，公司应当将 交易事项提交股东大会审议"的情况。出席会议的非关联董事一致同意该议案， 审议程序符合相关法律法规的规定。 公司独立董事专门会议审议通过该议案，并形成以下意见：全体独立董事认 为公司2024年度实施和2025年度预计的日常关联交易均属于公司与关联方之间 基于公司业务发展需要而发生的交易，交易根据自愿、平等、互利、 ...

经评估，公司认为大信资质等方面合规有效，履职保持独立性，勤勉尽责， 公允表达意见，具体情况如下： 一、资质条件 大信成立于 1985 年，2012 年 3 月转制为特殊普通合伙制事务所，总部位于 北京，注册地址为北京市海淀区知春路 1 号 22 层 2206，首席合伙人为谢泽敏 先生。截至 2024 年 12 月 31 日，从业人员总数 3,957 人，合伙人 175 人，注册 会计师 1,031 人，其中签署过证券服务业务审计报告的超过 500 人。 大信 2023 年度业务收入 15.89 亿元，为超过 10,000 家公司提供服务。业务 收入中，审计业务收入 13.80 亿元、证券业务收入 4.50 亿元。2023 年上市公司 年报审计客户 204 家（含 H 股），平均资产额 146.53 亿元，收费总额 2.41 亿元。 主要分布于制造业、信息传输、软件和信息技术服务业，电力、热力、燃气及 水生产和供应业，科学研究和技术服务业、水利、环境和公共设施管理业。 2023 年度本公司同行业上市公司审计客户 134 家。 北京英诺特生物技术股份有限公司 2024 年度会计师事务所的履职情况评估报告 北京英诺 ...

北京英诺特生物技术股份有限公司 未来三年（2025 年-2027 年）股东分红回报规划 北京英诺特生物技术股份有限公司（以下简称"公司"）为建立和完善对投 资者持续、稳定的回报规划与机制，保证利润分配政策的连续性和稳定性，切实 保护公众投资者的合法权益，根据《关于进一步落实上市公司现金分红有关事项 的通知》《上市公司监管指引第 3 号——上市公司现金分红》《上海证券交易所科 创板上市公司自律监管指引第 1 号——规范运作》和《北京英诺特生物技术股份 有限公司章程》（以下简称"《公司章程》"）的相关规定，结合经营发展需要，特 制定公司未来三年（2025 年-2027 年）股东分红回报规划，具体情况如下： 一、制定本规划考虑的因素 公司从可持续发展的角度出发，综合考虑公司经营发展实际情况、社会资金 成本和融资环境等方面因素，建立对投资者持续、稳定、科学、可预期的回报规 划和机制，对利润分配作出积极、明确的制度性安排，从而保证公司利润分配政 策的连续性和稳定性。 二、本规划的制定原则 本规划的制定应符合相关法律法规及《公司章程》有关利润分配的规定，在 遵循重视对股东的合理投资回报并兼顾公司可持续发展的原则上，充分听 ...

1、 专项审计报告 2、 附表 委托单位：北京英诺特生物技术股份有限公司 审计单位：大信会计师事务所（特殊普通合伙） 联系电话：010-83682249-8029 北京英诺特生物技术股份 有限公司 非经营性资金占用及其他关 联资金往来情况汇总表的专 项审计报告 大信专审字[2025]第 34-00008 号 关于北京英诺特生物技术股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 大信会计师事务所(特殊普通合伙)_ WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://www.mof.gov.cn）"近1 1 WHYIGE Certified Public Accountants I I P Room 2206 22/F. Xuevuan International Tower 传直 Fax: No.1 Zhichun Road, Haidian Dist. Belling, China, 100083 曲话 Telephone: +86 /10) 82330558 +86 (1 ...

北京英诺特生物技术股份有限公司 2024 年度审计委员会对会计师事务所 履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》和《公司章程》等规定和要求，董 事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将北京英诺特生 物技术股份有限公司（以下简称"公司"）董事会审计委员会对会计师事务所 2024 年度履行监督职责情况汇报如下： 一、2024 年度会计师事务所的履职情况 （一）会计师事务所基本情况 大信会计师事务所（特殊普通合伙）（以下简称"大信"）成立于 1985 年， 2012 年 3 月转制为特殊普通合伙制事务所，总部位于北京，注册地址为北京市 海淀区知春路 1 号 22 层 2206。大信在全国设有 33 家分支机构，在香港设立了 分所，并于 2017 年发起设立了大信国际会计网络，目前拥有美国、加拿大、澳 大利亚、德国、法国、英国、新加坡等 38 家网络成员所。大信是我国最早从事 证券服务业务的会计师事务所之一，首批获得 H 股企业审计 ...

证券代码：688253 证券简称：英诺特 公告编号：2025-020 北京英诺特生物技术股份有限公司关于召开 2024 年 度暨 2025 年第一季度业绩说明会的公告 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年度、2025 年第 一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 披露允许的范围内就投资者普遍关注的问题进行回答。 1 / 3 会议召开时间：2025 年 5 月 13 日（星期二）下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 5 月 6 日（星期二）至 2025 年 5 月 12 日（星期一） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公 司邮箱 ir@innovita.com.cn 进行提问。公司将在说明会上对投资者普遍 关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2025 年 5 月 13 日 ...